Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-06-11 | Nanexa | First patient dosed in Nanexa's Phase I trial of NEX-22 in type 2 diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-06-11 | Nanexa | Första patient doserad i Nanexas fas I-studie med NEX-22 inom typ 2-diabetes | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Nanexa | Kommuniké från årsstämma i Nanexa AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Nanexa | Bulletin from Nanexa’s Annual General Meeting | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Bulletin from Nanexa’s Annual General MeetingThe Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 15, 2024, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice. The income statement and balance sheet were adopted, together with the board of directors’ proposal for allocation of the company’s result. The board of directors and CEO were discharged from liability for the financial year 2023. Göran Ando, Richard Davis, Jakob Dynnes Hansen, Eva Nilsagård and Birgit Stattin Norinder were re-elected, and Hanna Tilus was elected, as members of the board. Göran Ando was re-elected as chairman of the board. The AGM voted on directors’ fees in accordance with the nomination committee’s proposal as follows: Remuneration shall be paid with SEK 260,000 for the chairman and with SEK 130,000 to other board members not employed by the company. Furthermore, SEK 100,000 shall be paid to the chairman of the audit committee and SEK 50,000 to each other member of the audit committee. The registered accounting firm Öhrlings PricewaterhouseCoopers AB was appointed auditor. Niclas Bergenmo will continue as auditor in charge. The proposal from the nomination committee regarding the establishment of a nomination committee and instructions to the nomination committee were approved. In accordance with the board of directors’ proposal, the AGM resolved on changes to the provisions of the articles of association concerning the limits for the company’s share capital and number of shares. The AGM further resolved to adopt the board of directors’ proposals regarding authorizations for the board to decide on rights issues and directed issues. |
||||
2024-05-15 | Nanexa | Nanexa receives approval for NEX-22 clinical study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-15 | Nanexa | Nanexa erhåller godkännande för klinisk studie med NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-10 | Redeye | Redeye: Nanexa Q1 2024 - Insightful capital markets day | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-10 | Emergers | Emergers: Equity Research | NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-05-03 | Nanexa | Nanexa publishes interim report for January-March 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-05-03 | Nanexa | Nanexa publicerar delårsrapport för januari-mars 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-30 | Nanexa | Invitation to comment on Nanexa's Q1 report 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-30 | Nanexa | Inbjudan till kommentar av Nanexas Q1-rapport 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-29 | Nanexa | Nanexa invites to Capital Markets Day on May 7 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-29 | Nanexa | Nanexa bjuder in till kapitalmarknadsdag 7 maj | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Nanexa | Godkännandet av klinisk prövningsansökan för NEX-22-studien försenas | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Nanexa | Approval of clinical trial application for NEX-22 study delayed | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-15 | Nanexa | Notice of annual general meeting in Nanexa AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-15 | Nanexa | Kallelse till årsstämma Nanexa AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Nanexa | Nanexa publicerar årsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-03-27 | Nanexa | Nanexa publishes annual report for 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Redeye | Redeye: Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-22 | Emergers | Emergers: Equity Research | NANEXA: Focus on dual GLP-1 opportunities and the partner projects | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Nanexa | Nanexa publishes year-end report and Q4 report 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-21 | Nanexa | Nanexa publicerar bokslutskommuniké och Q4-rapport 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-20 | Nanexa | Invitation to presentation of Nanexa's year-end report and Q4 report 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-20 | Nanexa | Inbjudan till presentation av Nanexas bokslutskommuniké och Q4-rapport 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-21 | Emergers | Emergers: Equity Research | NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Nanexa | Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Nanexa | Nanexa optimizes business operations through tactical priorities | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Nanexa | Nanexas kliniska prövningsansökan för NEX-22 fas I-studie emottagen av EMA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Nanexa | Nanexa optimerar affärsverksamheten genom taktiska prioriteringar | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Nanexa | Nanexa changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-30 | Nanexa | Nanexa byter Certified Adviser till Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | Nanexa | Nanexa tecknar utvärderingsavtal med ett stort globalt läkemedelsbolag | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-29 | Nanexa | Nanexa signs evaluation agreement with a large global pharmaceutical company | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-21 | Redeye | Redeye: Nanexa Q3 - Focused approach | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-21 | Emergers | Emergers: Equity Research | NANEXA: Raising our LOAs following a review of the projects | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-20 | Nanexa | Nanexa publishes interim report for January – September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-20 | Nanexa | Nanexa publicerar delårsrapport för januari-september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Nanexa | Nanexa presenterade hälsoekonomiska data på internationell kongress | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Nanexa | Nanexa presented Health Economical data at international conference | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-01 | Emergers | Emergers: Equity Research | NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-30 | Nanexa | Nanexa offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-30 | Nanexa | Nanexa announces outcome of rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-20 | Nanexa | Nanexa erhåller ytterligare teckningsförbindelse i pågående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-20 | Nanexa | Nanexa receives additional subscription undertaking in the ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Nanexa | Nanexa publishes EU growth prospectus in connection with rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Nanexa | Nanexa offentliggör EU-tillväxtprospekt med anledning av företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Nanexa | Nanexa reports preliminary key financial information for the period January-September 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Nanexa | Nanexa rapporterar preliminär finansiell nyckelinformation för perioden januari-september 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-11 | Emergers | Emergers: Equity Research | NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Nanexa | Nanexa completes clinical phase I study with NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Nanexa | Nanexa har slutfört den kliniska fas I-studien med NEX-20 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-28 | Nanexa | Nanexa bjuder in till investerarmöte 9 oktober i Uppsala | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-28 | Nanexa | Nanexa invites to investor meeting on October 9th in Uppsala | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-22 | Nanexa | Invitation to commentary regarding rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-22 | Nanexa | Inbjudan till kommentar gällande företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-22 | Emergers | Emergers: NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-21 | Nanexa | Nanexa carries out a rights issue of approximately SEK 121 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-21 | Nanexa | Nanexa genomför en företrädesemission om cirka 121 MSEK | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-06 | Nanexa | Nanexa presenterar vid ISPOR Europe 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-06 | Nanexa | Nanexa presents at ISPOR Europe 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-30 | Nanexa | Nanexa beviljas patent i Indien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-30 | Nanexa | Nanexa is granted patent in India | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Redeye | Redeye: Nanexa Q2 - Solid progress but a capital injection is on the horizon | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Emergers | Emergers: Equity Research | NANEXA: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Nanexa | Nanexa publicerar delårsrapport för januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-23 | Nanexa | Nanexa publishes interim report for January – June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-22 | Nanexa | Invitation to presentation of Nanexa’s Q2 report 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-22 | Nanexa | Inbjudan till presentation av Nanexas Q2-rapport 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-22 | Nanexa | Nanexa bekräftar fortsatt positiva resultat från en ny preklinisk studie av NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-22 | Nanexa | Nanexa confirms continued positive results from a new preclinical study of NEX-22 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-22 | Nanexa | Nanexa obtains pharmacokinetic data from the NEX-20 Phase 1 study confirming controlled release of lenalidomide | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-22 | Nanexa | Nanexa erhåller farmakokinetiska data från den kliniska fas I-studien med NEX-20 som konfirmerar kontrollerad frisättning av lenalidomid | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-10 | Nanexa | Summer letter from Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-10 | Nanexa | Sommarbrev från Nanexa | Pressreleaser | Ladda ner | Visa Stäng |
|